| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 29 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 29 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 29 |
| 3 | DOXORUBICIN | 24 |
| 4 | ETOPOSIDE | 24 |
| 5 | HYDROXYUREA | 23 |
| 6 | CISPLATIN | 15 |
| 7 | ONDANSETRON | 14 |
| 8 | ONDANSETRON HYDROCHLORIDE | 14 |
| 9 | PREDNISOLONE | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | RELACORILANT | 1 | 0.0101 |
| 1 | SETMELANOTIDE | 1 | 0.0035 |
| 2 | ELAPEGADEMASE-LVLR | 1 | 0.0033 |
| 3 | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | 1 | 0.0033 |
| 4 | BUTENAFINE HYDROCHLORIDE | 1 | 0.0017 |
| 5 | ZIV-AFLIBERCEPT | 2 | 0.0015 |
| 6 | CICLOPIROX | 3 | 0.0012 |
| 7 | HYDROXYUREA | 23 | 0.0011 |
| 8 | EFINACONAZOLE | 2 | 0.0010 |
| 9 | PSYLLIUM HUSK | 1 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 30 |
| 1 | Alkylating Drug [EPC] | 29 |
| 2 | Platinum-based Drug [EPC] | 25 |
| 3 | Topoisomerase Inhibitor [EPC] | 24 |
| 4 | Antimetabolite [EPC] | 23 |
| 5 | Microtubule Inhibitor [EPC] | 16 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 15 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 14 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 14 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 14 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Melanocortin 4 Receptor Agonist [EPC] | 1 | 0.0035 |
| 1 | Sulfonamide Antibacterial [EPC] | 2 | 0.0005 |
| 2 | Actinomycin [EPC] | 1 | 0.0005 |
| 3 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 3 | 0.0003 |
| 4 | Topoisomerase Inhibitor [EPC] | 24 | 0.0003 |
| 5 | Carnitine Analog [EPC] | 1 | 0.0003 |
| 6 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 5 | 0.0002 |
| 7 | Non-Standardized Insect Allergenic Extract [EPC] | 1 | 0.0002 |
| 8 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 9 | Standardized Insect Venom Allergenic Extract [EPC] | 1 | 0.0001 |